TMS Co

TMS Co Enterprise Value

The Enterprise Value (EV) of TMS Co (4891.T) as of Nov 4, 2026 is 3.59 B JPY. In the previous year, Enterprise Value (EV) was 3.45 B JPY — a change of 4.12% (higher).

Enterprise Value

3.59 BJPY

YoY

4.12%

Last updated:

Enterprise Value (EV) of TMS Co is 2026 3.59 B JPY. Enterprise Value (EV) of TMS Co was 2025 3.45 B JPY. It decreases by 4.12% higher compared to the previous year.

The TMS Co Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2021
5.26 B JPY
Jan 1, 2022
3.77 B JPY
Jan 1, 2023
2.78 B JPY
Jan 1, 2024
2.92 B JPY
Jan 1, 2025
3.45 B JPY
Jan 1, 2026
3.59 B JPY
The TMS Co Enterprise Value history
YEAREnterprise ValueYoY
3.59 BJPY+4.12%
3.45 BJPY+17.93%
2.92 BJPY+4.96%
2.78 BJPY-26.17%
3.77 BJPY-28.34%
5.26 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

Enterprise Value (EV) of TMS Co is 3.59 B JPY in 2026.

Enterprise Value (EV) of TMS Co changed from 3.45 B JPY to 3.59 B JPY, representing a 4.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) TMS Co since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s JPY, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' JPY varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s TMS Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — TMS Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — TMS Co